ProCE Banner Activity


Updates in Metastatic Prostate Cancer Care: Expert Guidance for Multidisciplinary Community Practice and VHA Systems


Watch this on-demand webcast from a live webinar on optimizing multidisciplinary care of patients with metastatic prostate cancer for healthcare professionals practicing in the community and Veterans Affairs

Pharmacists: 1.00 contact hour (0.1 CEUs)

Nurses: 1.00 Nursing contact hour

Physicians: Maximum of 1.00 AMA PRA Category 1 Credit

Released: June 19, 2023

Expiration: June 18, 2024

No longer available for credit.



Daniel P. Petrylak

Daniel P. Petrylak, MD

Professor of Medicine (Medical Oncology) and of Urology
Director, Prostate and GU Medical Oncology
Yale Cancer Center
New Haven, Connecticut

Provided by

Provided by Clinical Care Options, LLC

ProCE Banner


Supported by educational grants from Astellas, AstraZeneca Pharmaceuticals, Bayer HealthCare Pharmaceuticals Inc., Merck Sharp & Dohme Corp., and Sanofi Genzyme


AstraZeneca Pharmaceuticals

Bayer HealthCare Pharmaceuticals Inc.

Merck Sharp & Dohme Corp.

Sanofi Genzyme

Target Audience

This program is intended for oncologists, nurses, pharmacists, and other healthcare professionals on the multidisciplinary team caring for patients with prostate cancer.

Program Learning Goal

The goal of this activity is to improve learners’ knowledge, competence, and performance in applying practice-changing clinical data and expert recommendations to integrate the use of currently available therapies for their patients with metastatic prostate cancer.

Learning Objectives

Upon completion of this activity, participants should be able to:

  • Evaluate novel therapeutically actionable molecular targets that hold promise as predictive or prognostic biomarkers for patients with metastatic prostate cancer

  • Plan optimal, individualized sequential therapeutic strategies for metastatic prostate cancer, considering all available agents, clinical data including novel imaging techniques, and expert recommendations

  • Counsel patients with metastatic prostate cancer on available therapies, taking into consideration patient preferences regarding differences in administration and safety profiles, as well as comorbidities and patient goals

  • Identify patients with metastatic prostate cancer who may be eligible for enrollment on ongoing clinical studies investigating novel regimens


Clinical Care Options, LLC (CCO) requires instructors, planners, managers, and other individuals who are in a position to control the content of this activity to disclose all financial conflicts of interest (COI) they may have with ineligible companies. All relevant COI are thoroughly vetted and mitigated according to CCO policy. CCO is committed to providing its learners with high-quality CME/CE activities and related materials that promote improvements or quality in healthcare and not a specific proprietary business interest of an ineligible company.

The faculty reported the following relevant financial relationships or relationships to products or devices they have with ineligible companies related to the content of this educational activity:

Daniel P. Petrylak, MD: consultant/advisor/speaker: Ada Cap (Advanced Accelerator Applications) Amgen, Astellas, AstraZeneca, Bayer, Bicycle Therapeutics, Boehringer Ingelheim, Bristol-Myers Squibb, Clovis Oncology, Exelixis, Gilead Sciences, Incyte, Infinity Pharmaceuticals, Ipsen, Janssen, Lilly, Mirati, Monopteros, Pfizer, Pharmacyclics, Regeneron, Roche, Seattle Genetics, Urogen; researcher: Ada Cap (Advanced Accelerator Applications), Agensys Inc, Arvinas, Astellas, AstraZeneca, Bayer, BioXcel Therapeutics, Bristol-Myers Squibb, Clovis Oncology, Eisai, Endocyte, Genentech, Gilead Sciences, Innocrin, Lilly, MedImmune, Medivation, Merck, Mirati, Novartis, Pfizer, Progenics, Replimune, Roche, Sanofi Aventis, Seattle Genetics

The planners and content peer reviewers from Clinical Care Options, LLC do not have any relevant financial relationships to disclose.

Instructions for Credit

Participation in this self-study activity should be completed in approximately 1 hours. To successfully complete this activity and receive credit, learners must follow these steps during the period from June 19, 2023, through June 18, 2024:
1. Login or Sign Up for an account by clicking at the top of this page.
2. Read the target audience, learning objectives, and faculty disclosures.
3. View and study the content in its entirety.
4. Submit answers to the posttest questions and evaluation questions online.
You must receive a test score of at least 65 and respond to all evaluation questions to receive a certificate. After submitting the evaluation, you may access your online certificate by clicking the certificate link on the confirmation page. Records of all CME/CE activities completed can be found on the "My Certificates" page. There are no costs/fees for this activity.


This program has been made available online.

Disclosure of Unlabeled Use

This educational activity may contain discussion of published and/or investigational uses of agents that are not indicated by the FDA. The planners of this activity do not recommend the use of any agent outside of the labeled indications.

The opinions expressed in the educational activity are those of the faculty and do not necessarily represent the views of the planners. Please refer to the official prescribing information for each product for discussion of approved indications, contraindications, and warnings.


Participants have an implied responsibility to use the newly acquired information to enhance patient outcomes and their own professional development. The information presented in this activity is not meant to serve as a guideline for patient management. Any procedures, medications, or other courses of diagnosis or treatment discussed or suggested in this activity should not be used by clinicians without evaluation of their patient’s conditions and possible contraindications and/or dangers in use, review of any applicable manufacturer’s product information, and comparison with recommendations of other authorities.


Joint Accreditation Statement

In support of improving patient care, Clinical Care Options, LLC (CCO) is jointly accredited by the Accreditation Council for Continuing Medical Education (ACCME), the Accreditation Council for Pharmacy Education (ACPE), and the American Nurses Credentialing Center (ANCC), to provide continuing education for the healthcare team.

Physician Continuing Medical Education

CCO designates this enduring material for a maximum of 1 AMA PRA Category 1 Credits™. Physicians should claim only the credit commensurate with the extent of their participation in the activity.

Nursing Continuing Professional Development

The maximum number of hours awarded for this Nursing Continuing Professional Development activity is 1 contact hour.

Continuing Pharmacy Education

CCO designates this continuing education activity for 1 contact hour (0.1 CEUs) of the Accreditation Council for Pharmacy Education.
Universal Activity Number - JA4008176-0000-23-173-H01-P 
Type of Activity: Application 

Upon successfully completing the post-test with a score of 65 or better and the activity evaluation form, transcript information will be sent to the NABP CPE Monitor Service within 60 days.